• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pharmather Hldgs Ltd (OP: PHRRF )

    0.1550 -0.0051 (-3.19%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 209,140
    Open 0.1675
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1601
    Today's Range 0.1500 - 0.1675
    52wk Range 0.0831 - 0.3200
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -37.25%
    -37.25%
    1 Month
    -3.13%
    -3.13%
    3 Month
    -3.37%
    -3.37%
    6 Month
    +8.47%
    +8.47%
    1 Year
    +40.78%
    +40.78%

    More News

    Read More
    PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
    Via Benzinga
    PharmaTher Provides Update for Expected FDA Approval of Ketamine
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
    Via Benzinga
    PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
    Via Benzinga
    Exposures Product Safety
    PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
    Via Benzinga
    Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
    Via Benzinga
    Exposures Product Safety
    PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
    Via Benzinga
    PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
    Via Benzinga
    PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
    From PharmaTher Holdings Ltd.
    Via GlobeNewswire
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    Via Benzinga
    BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
    Via Benzinga
    Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.